Company: CI
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001739940-25-000037
Chunk: 109

Company: Cigna Group
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 1
Chunk 109
---
138 Total special items$174 (61)$346 300 $767 339 $465 367 Adjusted income from operations$2,096 $2,112 $5,866 $5,896 

(1)Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.

(2)Represents amortization of a foreign tax attribute. See Note 20 to the Consolidated Financial Statements in our 2024 Form 10-K for additional details.

Reconciliation of Shareholders' Net Income (GAAP) to Adjusted Income from OperationsThree Months Ended September 30,Nine Months Ended September 30,2025202420252024(Diluted earnings per share)Pre-taxAfter-taxPre-taxAfter-taxPre-taxAfter-taxPre-taxAfter-taxShareholders' net income$6.98 $2.63 $17.52 $7.05 Adjustments to reconcile to adjusted income from operationsNet investment (gains) losses (1)$(0.76)(0.16)$2.64 2.63 $(1.29)(0.72)$9.00 8.93 Amortization of acquired intangible assets1.63 1.24 1.55 1.18 4.74 3.70 4.49 3.41 Special itemsStrategic optimization program0.82 0.63 — — 2.10 1.59 — — Integration and transaction-related costs0.03 0.02 0.27 0.21 1.10 0.84 0.62 0.48 (Gain) loss on sale of businesses (0.14)(0.90)0.31 0.22 (0.29)(1.32)0.37 0.07 (Benefits) associated with litigation matters(0.06)(0.05)— — (0.06)(0.05)— — Deferred tax expenses, net (2)— 0.07 — 0.15 — 0.20 — 0.26 Impairment of dividend receivable —